BRPI0510458A - compostos quìmicos - Google Patents

compostos quìmicos

Info

Publication number
BRPI0510458A
BRPI0510458A BRPI0510458-0A BRPI0510458A BRPI0510458A BR PI0510458 A BRPI0510458 A BR PI0510458A BR PI0510458 A BRPI0510458 A BR PI0510458A BR PI0510458 A BRPI0510458 A BR PI0510458A
Authority
BR
Brazil
Prior art keywords
chemical compounds
hydrated
crystalline
pharmaceutical
derivatives
Prior art date
Application number
BRPI0510458-0A
Other languages
English (en)
Inventor
Peter David Tiffin
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of BRPI0510458A publication Critical patent/BRPI0510458A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSTOS QUìMICOS. A presente invenção refere-se a novas formas amorfas, cristalinas, hidratadas e solvatadas, e o uso destas na fabricação de esmilagenina farmacêutica ou de grau comestível e seus derivados.
BRPI0510458-0A 2004-04-28 2005-04-28 compostos quìmicos BRPI0510458A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409567.5A GB0409567D0 (en) 2004-04-28 2004-04-28 Chemical compounds
PCT/GB2005/001635 WO2005105825A2 (en) 2004-04-28 2005-04-28 Crystalline and amorphous forms of smilagenin

Publications (1)

Publication Number Publication Date
BRPI0510458A true BRPI0510458A (pt) 2007-10-30

Family

ID=32408243

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510458-0A BRPI0510458A (pt) 2004-04-28 2005-04-28 compostos quìmicos

Country Status (17)

Country Link
US (2) US20080004249A1 (pt)
EP (2) EP2402362A2 (pt)
JP (1) JP2007534736A (pt)
KR (1) KR20070028387A (pt)
CN (2) CN101076539A (pt)
AU (1) AU2005238274A1 (pt)
BR (1) BRPI0510458A (pt)
CA (1) CA2564368A1 (pt)
GB (1) GB0409567D0 (pt)
IL (1) IL178870A0 (pt)
MX (1) MXPA06012641A (pt)
NO (1) NO20065485L (pt)
RU (1) RU2006141389A (pt)
SG (1) SG155165A1 (pt)
TW (1) TW200538145A (pt)
WO (1) WO2005105825A2 (pt)
ZA (1) ZA200609596B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084356A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
AU2011281336B2 (en) 2010-07-20 2015-03-05 Junaxo, Inc. Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL292786A (pt) * 1962-05-15
US3169959A (en) * 1963-07-23 1965-02-16 Intermediates Inc Method of obtaining smilagenin
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
PL195897B1 (pl) * 1998-03-26 2007-11-30 Phytopharm Plc Zastosowanie smilageniny
GB9905275D0 (en) 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
AT409100B (de) 2000-07-24 2002-05-27 Evg Entwicklung Verwert Ges Vorrichtung zum schweissen einer drahtgittermatte
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
KR20100093621A (ko) 2002-03-27 2010-08-25 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도
PL210114B1 (pl) 2002-10-28 2011-12-30 Phytopharm Plc Sposób stereospecyficznego wytwarzania 3β-hydroksy-5β-H-steroidowych sapogenin

Also Published As

Publication number Publication date
CN101076539A (zh) 2007-11-21
CN102516352A (zh) 2012-06-27
AU2005238274A1 (en) 2005-11-10
KR20070028387A (ko) 2007-03-12
WO2005105825A3 (en) 2006-02-23
CA2564368A1 (en) 2005-11-10
JP2007534736A (ja) 2007-11-29
SG155165A1 (en) 2009-09-30
RU2006141389A (ru) 2008-06-10
MXPA06012641A (es) 2006-12-15
WO2005105825A2 (en) 2005-11-10
NO20065485L (no) 2007-01-29
IL178870A0 (en) 2007-03-08
US20110144323A1 (en) 2011-06-16
GB0409567D0 (en) 2004-06-02
EP1742960A2 (en) 2007-01-17
EP2402362A2 (en) 2012-01-04
ZA200609596B (en) 2008-01-30
US20080004249A1 (en) 2008-01-03
TW200538145A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
ATE502172T1 (de) Vorrichtung für den einsatz beim bau von gebäuden
AR061024A1 (es) Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
BRPI0512060A (pt) compostos orgánicos
AR072777A1 (es) Formas solidas de clorhidrato de bendamustina
ATE393764T1 (de) Polymorphe formen von valsartan
ECSP045221A (es) Sales de valsartan
EP1856236A4 (en) AQUEOUS DISINFECTANTS AND STERILIZERS
AR051470A1 (es) Criatales estables de natamicina en forma de aguja
CR9993A (es) Formulación de suspensión de fexofenadina
ECSP12007431A (es) Compuestos orgánicos
BRPI0418378A (pt) combinações de substáncias ativas com propriedades inseticidas
CR10846A (es) Formas cristalinas glyt1
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
BRPI0818121A2 (pt) diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
CY1112121T1 (el) ΠΑΡΑΓΩΓΑ ΤΩΝ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-[1,2-α]-ΠΥΡΑΖΙΝ-6-ΚΑΡΒΟΞΑΜΙΔΙΩΝ ΚΑΙ ΤΩΝ 2,3,4,5-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-(1,2-α)-ΔΙΑΖΕΠΙΝ-7-ΚΑΡΒΟΞΑΜΙΔΙΩΝ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ
WO2007134845A3 (en) Olanzapine pharmaceutical composition
BRPI0510458A (pt) compostos quìmicos
BRPI0606636A2 (pt) compostos macrocìclicos úteis como inibidores de bace
HN2006029142A (es) Proceso
ZA200800471B (en) Methods of altering poppy characteristics
ECSP109874A (es) Nuevos compuestos 892
DE602005006105D1 (de) Membrankörper und entsprechendes herstellungsverfahren
CY1108501T1 (el) Συνθεση δια την προληψη και θεραπευτικη αγωγη ασθενειων κρυολογηματος
BRPI0517648A (pt) compostos quìmicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.